Hypofraction Radiotherapy for Limited-Stage Small Cell Lung Cancer

Not Applicable

Completed

• Conditions: Safety Issues; Efficacy, Self

• Registration Number: NCT05523908
• Lead Sponsor: Anhui Provincial Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-8-29
• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Inclusion Criteria:<br><br> - 18-75 years old;<br><br> - ECOG 0-1;<br><br> - Small cell lung cancer;<br><br> - Limited stage confirmed by cranial MRI, chest CT, abdominal ultrasonagraph, bone<br> scan or cranial MRI and PET-CT;<br><br> - Signature of inform consent.<br><br>Exclusion Criteria:<br><br> - Younger than 18 years old or older than 75 years old;<br><br> - ECOG>1;<br><br> - Non-small cell lung cancer and other neuroendocrine carcinoma including typical or<br> atypical carcinoid, large-cell neuroendocrine carcinoma;<br><br> - Extensive stage confirmed by cranial MRI, chest CT, abdominal ultrasonagraph, bone<br> scan or cranial MRI and PET-CT;<br><br> - No signature of inform consent.

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Rate of radiation-induced pneumonitis (CTCAE V4.0);Rate of radiation-induced esophagitis (CTCAE V4.0);Rate of myelosuppression (CTCAE V4.0)

Secondary Outcome Measures

Name	Time	Method
2 year locoregional control rate (RECIST 1.1)